DE69738000T2 - Neue Arzneiformulierung enthaltend Budesonide - Google Patents

Neue Arzneiformulierung enthaltend Budesonide Download PDF

Info

Publication number
DE69738000T2
DE69738000T2 DE69738000T DE69738000T DE69738000T2 DE 69738000 T2 DE69738000 T2 DE 69738000T2 DE 69738000 T DE69738000 T DE 69738000T DE 69738000 T DE69738000 T DE 69738000T DE 69738000 T2 DE69738000 T2 DE 69738000T2
Authority
DE
Germany
Prior art keywords
unit dose
amount
dose according
budesonide
thickener
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69738000T
Other languages
German (de)
English (en)
Other versions
DE69738000D1 (de
Inventor
Gordon Santesson
Hans Nilsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26662810&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69738000(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9604486A external-priority patent/SE9604486D0/xx
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE69738000D1 publication Critical patent/DE69738000D1/de
Application granted granted Critical
Publication of DE69738000T2 publication Critical patent/DE69738000T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69738000T 1996-12-05 1997-11-28 Neue Arzneiformulierung enthaltend Budesonide Revoked DE69738000T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9604486A SE9604486D0 (sv) 1996-12-05 1996-12-05 Novel formulation
SE9604486 1996-12-05
US08/846,960 US6291445B1 (en) 1996-12-05 1997-04-29 Low dose budesonide formulations and uses thereof
US846960 1997-04-29

Publications (2)

Publication Number Publication Date
DE69738000D1 DE69738000D1 (de) 2007-09-20
DE69738000T2 true DE69738000T2 (de) 2008-04-17

Family

ID=26662810

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69738000T Revoked DE69738000T2 (de) 1996-12-05 1997-11-28 Neue Arzneiformulierung enthaltend Budesonide
DE69721766T Revoked DE69721766T2 (de) 1996-12-05 1997-11-28 Neue arzneiformulierung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69721766T Revoked DE69721766T2 (de) 1996-12-05 1997-11-28 Neue arzneiformulierung

Country Status (22)

Country Link
US (2) US6686346B2 (enExample)
EP (1) EP0907365B1 (enExample)
JP (1) JP2000508675A (enExample)
CN (1) CN1168450C (enExample)
AT (2) ATE239482T1 (enExample)
AU (1) AU726515B2 (enExample)
BE (1) BE1011394A5 (enExample)
CZ (1) CZ295792B6 (enExample)
DE (2) DE69738000T2 (enExample)
DK (1) DK0907365T3 (enExample)
ES (1) ES2133130B1 (enExample)
FR (1) FR2756739B1 (enExample)
GR (1) GR1003011B (enExample)
HU (1) HUP0000575A3 (enExample)
IE (1) IE970854A1 (enExample)
IL (1) IL125534A (enExample)
NL (1) NL1007706C2 (enExample)
NO (1) NO983555L (enExample)
NZ (1) NZ330925A (enExample)
PT (1) PT907365E (enExample)
TR (1) TR199801501T1 (enExample)
WO (1) WO1998024450A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
WO2005027853A2 (en) * 2003-09-19 2005-03-31 University Of Louisville Research Foundation Inc Method for treating snoring and sleep apnea with leukotriene antagonists
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070110788A1 (en) * 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US7993675B2 (en) * 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7976873B2 (en) * 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US7959943B2 (en) * 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
US8088095B2 (en) 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
US8865692B2 (en) * 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
WO2009064819A2 (en) 2007-11-13 2009-05-22 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
EP2303254B1 (en) 2008-06-12 2019-10-30 Medtronic Xomed, Inc. Product for treating chronic wounds with an extracellular polymeric substance solvating system
EP2346324A4 (en) 2008-10-06 2012-10-10 Microbial Defense Systems Llc ANTIMICROBIAL COMPOSITION AND METHODS OF MAKING AND USING
CA2765033C (en) * 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
JP6463629B2 (ja) 2011-05-10 2019-02-06 ネクスト サイエンス アイピー ホールディングス ピーティワイ エルティーディ 抗菌性固体およびその製造方法
CN112516087B (zh) * 2020-12-24 2023-03-24 四川普锐特药业有限公司 布地奈德鼻喷剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992534A (en) * 1972-05-19 1976-11-16 Ab Bofors Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
SE378109B (enExample) * 1972-05-19 1975-08-18 Bofors Ab
PL164294B1 (pl) * 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
SK285910B6 (sk) * 1991-12-18 2007-10-04 Aktiebolaget Astra Medicinálny produkt obsahujúci kombináciu formoterolu a budesonidu
GB2269992A (en) * 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
US5509404A (en) 1994-07-11 1996-04-23 Aradigm Corporation Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values
AU6290396A (en) * 1995-06-29 1997-01-30 Mcneil-Ppc, Inc. The combination of topical nasal mast cell stabilizers and topical nasal steroids
WO1997001337A1 (en) 1995-06-29 1997-01-16 Mcneil-Ppc, Inc. The combination of topical nasal antihistamines and topical nasal steroids
EP0780127A1 (en) * 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
EP0954318A1 (en) * 1996-06-04 1999-11-10 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
SE9604486D0 (sv) * 1996-12-05 1996-12-05 Astra Ab Novel formulation

Also Published As

Publication number Publication date
US6686346B2 (en) 2004-02-03
BE1011394A5 (fr) 1999-08-03
EP0907365A1 (en) 1999-04-14
AU726515B2 (en) 2000-11-09
DE69738000D1 (de) 2007-09-20
HK1020522A1 (en) 2000-05-12
FR2756739A1 (fr) 1998-06-12
DK0907365T3 (da) 2003-08-04
NO983555D0 (no) 1998-08-03
GR1003011B (el) 1998-11-20
EP0907365B1 (en) 2003-05-07
IE970854A1 (en) 1998-10-07
AU5421198A (en) 1998-06-29
IL125534A (en) 2003-06-24
US6986904B2 (en) 2006-01-17
ES2133130B1 (es) 2000-03-01
IL125534A0 (en) 1999-04-11
DE69721766T2 (de) 2004-03-04
HUP0000575A2 (hu) 2000-10-28
CZ243798A3 (cs) 1998-11-11
GR970100477A (el) 1998-08-31
PT907365E (pt) 2003-09-30
NL1007706C2 (nl) 1998-09-22
HUP0000575A3 (en) 2001-03-28
NL1007706A1 (nl) 1998-06-08
ATE239482T1 (de) 2003-05-15
ES2133130A1 (es) 1999-08-16
CN1210467A (zh) 1999-03-10
TR199801501T1 (xx) 1999-02-22
US20020016315A1 (en) 2002-02-07
US20040101486A1 (en) 2004-05-27
WO1998024450A1 (en) 1998-06-11
FR2756739B1 (fr) 2000-04-28
ATE369118T1 (de) 2007-08-15
NO983555L (no) 1998-08-03
NZ330925A (en) 2000-05-26
DE69721766D1 (de) 2003-06-12
JP2000508675A (ja) 2000-07-11
CN1168450C (zh) 2004-09-29
CZ295792B6 (cs) 2005-11-16

Similar Documents

Publication Publication Date Title
DE69738000T2 (de) Neue Arzneiformulierung enthaltend Budesonide
DE69526425T2 (de) Verwendung von mometasone-furoat zur behandlung von luftweg- und lungenerkrankungen
DE69938390T2 (de) Verwendung einer zusammensetzung welche formoterol und budesonide enthält, zur verhinderung oder behandlung eines akuten astmazustandes
US6291445B1 (en) Low dose budesonide formulations and uses thereof
DE60006262T2 (de) Topische suspensionsformulierungen enthaltend ciprofloxacin und dexamethason
AT404553B (de) Verwendung von ciclosporin zur pulmonalen verabreichung
DE1492015A1 (de) Verbesserte Verabreichungsform pharmazeutischer Praeparate
DE69002718T2 (de) Medikamente.
DE60002885T2 (de) Wässrige formulierung zur nasalen verabreichung
EP0125634A1 (de) Verwendung einer sekretolytisch wirkenden Substanz zur Herstellung eines Antischnarchmittels und zur Bekämpfung des Schnarchphänomens
WO2013034299A1 (de) Therapeutische anwendungen von ectoin
DE3317530A1 (de) Antischnarchmittel
DE60003183T2 (de) Formulierungen von steroidlösungen zur inhalativen verabreichung
DE3146570C2 (enExample)
DE102011103347B4 (de) Nasale pharmazeutische Formulierung
DE3852717T2 (de) Zusammensetzung für die Prophylaxe von Pneumocystis-carinii-Pneumonie.
EP2818167A1 (de) Antiviral wirksame pharmazeutische Zusammensetzung
EP3407890A1 (de) Pharmazeutische zubereitung und deren verwendung bei viralen, entzündlichen erkrankungen der oberen atemwege
DE60202299T2 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten
AT523662A1 (de) Gold-haltige Mittel zur Behandlung von Lungeninfektionen
HK1020522B (en) Novel formulation

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation